Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Lublinie, Uniwersytet Medyczny W BiałymstokufiledCriticalUniwersytet Medyczny W Lublinie
Priority to PL401992ApriorityCriticalpatent/PL221216B1/en
Publication of PL401992A1publicationCriticalpatent/PL401992A1/en
Publication of PL221216B1publicationCriticalpatent/PL221216B1/en
Przedmiotem wynalazku jest 2-benzoiloamino-5-(izochinolin-3-ylo)-1,3,4-tiadiazol o wzorze 1, sposób jego wytwarzania, zastosowanie związku o wzorze 1 jako leku do leczenia nowotworów piersi oraz jako substancji aktywnej do wytwarzania środków farmaceutycznych do leczenia nowotworów piersi.The subject of the invention is 2-benzoylamino-5- (isoquinolin-3-yl) -1,3,4-thiadiazole of formula 1, a method for its preparation, the use of a compound of formula 1 as a medicine for the treatment of breast cancer and as an active substance for the preparation of agents pharmaceuticals for treating breast cancer.
PL401992A2012-12-112012-12-112-benzoylamino-5-(isoquinolin-3-yl) -1,3,4-thiadiazole, a method for its preparation and the medical use
PL221216B1
(en)
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer